Trial Profile
A PHASE 1, RANDOMIZED, 2-WAY CROSSOVER, SINGLE DOSE, OPEN LABEL STUDY TO ESTIMATE THE EFFECT OF PF-04965842 ON DABIGATRAN PHARMACOKINETICS IN HEALTHY PARTICIPANTS
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Abrocitinib (Primary) ; Dabigatran etexilate
- Indications Atopic dermatitis; Prurigo nodularis; Pruritus
- Focus Pharmacokinetics
- Sponsors Pfizer
- 28 Mar 2022 Results published in the Clinical Pharmacology and Therapeutics
- 18 Mar 2022 Results presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 14 Mar 2019 Status changed from recruiting to completed.